Body Cavity–Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma

다국어 초록 (Multilingual Abstract)

Purpose Primary effusion lymphoma (PEL) is a type of body cavity–based lymphoma (BCBL). Most patients with PEL are severely immunocompromised and seropositive for human immunodeficiency virus (HIV). We investigated the distinctive clinicopathologic characteristics of BCBL in a country with low HIV burden.
Materials and Methods We retrospectively collected data on the clinicopathologic characteristics, treatments, and outcomes of 17 consecutive patients with BCBL at nine institutions in Korea.
Results Latency-associated nuclear antigen 1 (LANA1) immunostaining indicated that six patients had PEL, six patients had human herpesvirus 8 (HHV8)–unrelated BCBL, and five patients had HHV8-unknown BCBL. The patients with PEL exhibited no evidence of immunodeficiency except for one who was HIV positive. One (20%) and four (80%) patients with PEL and six (100%) and zero (0%) patients with HHV8-unrelated BCBL were positive for CD20 and CD30 expression, respectively. The two patients with PEL (one HIV-positive and one HIV-negative patient) with the lowest proliferation activity as assessed by the Ki-67 labeling index survived for > 1 and > 4 years without chemotherapy, respectively, in contrast to the PEL cases in the literature, which mostly showed a high proliferation index and poor survival.
Conclusion PEL mostly occurred in ostensibly immunocompetent individuals and had a favorable outcome in Korea. A watchful waiting approach may be applicable for managing HIV-seronegative patients with PEL with a low Ki-67 labeling index. A possible trend was detected among LANA1, CD20, and CD30 expression in BCBL.

참고문헌 (Reference)

1 Swerdlow SH, "The 2016 revision of the World Health Organization classification of lymphoid neoplasms" 127 : 2375-2390, 2016

2 Cheson BD, "Revised response criteria for malignant lymphoma" 25 : 579-586, 2007

3 Younes A, "Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma" 30 : 2183-2189, 2012

4 Carbone A, "Proliferation in HHV-8-positive primary effusion lymphomas is associated with expression of HHV-8cyclin but independent of p27(kip1)" 156 : 1209-1215, 2000

5 Boulanger E, "Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS" 23 : 4372-4380, 2005

6 Jones D, "Primary-effusion lymphoma and Kaposi's sarcoma in a cardiac-transplant recipient" 339 : 444-449, 1998

7 Said JW, "Primary effusion lymphoma in women : report of two cases of Kaposi's sarcoma herpes virus-associated effusionbased lymphoma in human immunodeficiency virus-negative women" 88 : 3124-3128, 1996

8 Rodriguez J, "Primary effusion lymphoma in an HIV-negative patient with no serologic evidence of Kaposi's sarcoma virus" 41 : 185-189, 2001

9 Nador RG, "Primary effusion lymphoma : a distinct clinicopathologic entity associated with the Kaposi's sarcomaassociated herpes virus" 88 : 645-656, 1996

10 Chen YB, "Primary effusion lymphoma" 12 : 569-576, 2007

11 Hocqueloux L, "Longterm remission of an AIDS-related primary effusion lymphoma with antiviral therapy" 15 : 280-282, 2001

12 Cesarman E, "Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas" 332 : 1186-1191, 1995

13 Alexanian S, "KSHV/HHV8-negative effusion-based lymphoma, a distinct entity associated with fluid overload states" 37 : 241-249, 2013

14 Boulanger E, "Human herpesvirus-8(HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin" 8 : 707-710, 2008

15 Wu W, "Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma : report of a rare case and review of 54 cases in the literature" 140 : 258-273, 2013

16 Matsumoto Y, "Human herpesvirus 8-negative malignant effusion lymphoma : a distinct clinical entity and successful treatment with rituximab" 46 : 415-419, 2005

17 신정훈, "Human Herpesvirus 8–Unrelated Primary Effusion Lymphoma–Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone" 대한암학회 49 (49): 274-278, 2017

18 Hall JC, "HIV/AIDS in the post-HAART era: manifestations, treatment, and epidemiology" People’s Medical Publishing House 2011

19 Pro B, "Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma" 130 : 2709-2717, 2017

20 Choe KW, "Epidemiology of HIV/AIDS : current status, trend and prospect" 50 : 296-302, 2007

21 Oksenhendler E, "Complete remission of a primary effusion lymphoma with antiretroviral therapy" 57 : 266-, 1998

22 Kobayashi Y, "Comparison of human herpes virus 8 related primary effusion lymphoma with human herpes virus 8unrelated primary effusion lymphoma-like lymphoma on the basis of HIV : report of 2 cases and review of 212 cases in the literature" 117 : 132-144, 2007

23 Simonelli C, "Clinical features and outcome of primary effusion lymphoma in HIV-infected patients : a single-institution study" 21 : 3948-3954, 2003

24 Guillet S, "Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution" 91 : 233-237, 2016

25 Bhatt S, "CD30 targeting with brentuximab vedotin : a novel therapeutic approach to primary effusion lymphoma" 122 : 1233-1242, 2013

26 Connors JM, "Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma" 378 : 331-344, 2018

27 Jacobsen ED, "Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression" 125 : 1394-1402, 2015

28 Hermine O, "Body-cavitybased lymphoma in an HIV-seronegative patient without Kaposi's sarcoma-associated herpesvirus-like DNA sequences" 334 : 272-273, 1996

29 Boulanger E, "A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients" 2 : 172-179, 2001